Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial. - Yuan J; Gong J; Peng Z; Liu TS; Xu H; Yang J; Wei J; Jiang H; Deng Y; Wang Y; Qi C; Lyu C; et al. (British journal of cancer, 2026)